<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197456</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD POISE</org_study_id>
    <secondary_id>K23HD058799</secondary_id>
    <nct_id>NCT01197456</nct_id>
  </id_info>
  <brief_title>Predictors of Ovarian Insufficiency in Young Breast Cancer Patients</brief_title>
  <acronym>POISE</acronym>
  <official_title>Predictors of Ovarian Insufficiency Through Serial Exams in Young Breast Cancer Patients (POISE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than two million American women are breast cancer survivors. Approximately one-third of
      these women are premenopausal at diagnosis and face issues related to reproduction as they
      undergo cancer treatment. Ovarian function after breast cancer diagnosis has implications on
      breast cancer prognosis, choice of adjuvant therapy and reproductive issues such as desire
      for fertility or concerns about menopause. Therefore, tools to accurately predict ovarian
      function in breast cancer survivors could significantly impact physicians and patients in
      counseling, medical and surgical treatment choices, and consideration of fertility
      preservation options.

      The goal of this proposal is to identify pre-chemotherapy hormonal, genetic and ovarian
      imaging markers that can predict ovarian failure and characterize the course of ovarian
      function after chemotherapy. The investigators plan to follow a group of young women from
      breast cancer diagnosis to five years after chemotherapy. The investigators will study the
      following risk factors: blood hormone levels that reflect ovarian function, genetic mutations
      that affect how individuals metabolize chemotherapy, and ovarian size and egg count by MRI
      and ultrasound. The investigators hypothesize that these biomarkers are related to risk of
      ovarian insufficiency singly. After examining these individual risk factors for ovarian
      failure, the investigators will put them together into an Ovarian Failure Clinical Predictive
      Index. This index will be a tool similar to the Gail Model that can be used to determine
      individual risk for ovarian failure. This tool would assist young breast cancer patients and
      their physicians in making treatment decisions that would impact cancer survival and
      reproduction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2008</start_date>
  <completion_date type="Actual">July 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Number of participant without of menses for 12 months after breast cancer diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience Return of Menses After 3 Months of Amenorrhea</measure>
    <time_frame>Years 1-5</time_frame>
    <description>Number of participants who experience return of menses after 3 months of amenorrhea</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">232</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Insufficiency</condition>
  <condition>Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Exposed/chemotherapy</arm_group_label>
    <description>Breast cancer patients who will undergo chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unexposed</arm_group_label>
    <description>Breast cancer patients who will not undergo chemotherapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosis of breast cancer (Stages 0-III)

          -  Age &lt;=45

          -  Premenopausal (at least one menses over past year)

          -  Has a uterus and at least one ovary

        Exclusion Criteria:

          -  Prior chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Su HC, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, DeMichele A. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014 Dec 1;120(23):3691-8. doi: 10.1002/cncr.28942. Epub 2014 Jul 31.</citation>
    <PMID>25081546</PMID>
  </results_reference>
  <results_reference>
    <citation>Homer MV, Charo LM, Natarajan L, Haunschild C, Chung K, Mao JJ, DeMichele AM, Su HI. Genetic variants of age at menopause are not related to timing of ovarian failure in breast cancer survivors. Menopause. 2017 Jun;24(6):663-668. doi: 10.1097/GME.0000000000000817.</citation>
    <PMID>28118297</PMID>
  </results_reference>
  <results_reference>
    <citation>Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of antim√ºllerian hormone levels among commercially available immunoassays. Fertil Steril. 2014 Jun;101(6):1766-72.e1. doi: 10.1016/j.fertnstert.2014.02.046. Epub 2014 Apr 14.</citation>
    <PMID>24726216</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>July 18, 2019</results_first_submitted>
  <results_first_submitted_qc>April 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2020</results_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Hui-Chun Irene Su</investigator_full_name>
    <investigator_title>Professor of Obstetrics, Gynecology, and Reproductive Sciences</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Ovarian insufficiency</keyword>
  <keyword>Ovarian failure</keyword>
  <keyword>Reproduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exposed/Chemotherapy</title>
          <description>Breast cancer patients who will undergo chemotherapy</description>
        </group>
        <group group_id="P2">
          <title>Unexposed</title>
          <description>Breast cancer patients who will not undergo chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exposed/Chemotherapy</title>
          <description>Breast cancer patients who will undergo chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>Unexposed</title>
          <description>Breast cancer patients who will not undergo chemotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="171"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="5.1"/>
                    <measurement group_id="B2" value="41.0" spread="5.7"/>
                    <measurement group_id="B3" value="39.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis</title>
        <description>Number of participant without of menses for 12 months after breast cancer diagnosis</description>
        <time_frame>Years 1-5</time_frame>
        <population>25 participants could not be evaluated for this outcome due to censoring for cancer recurrence, death, bilateral salpingo-oophorectomy, or hysterectomy.
38 additional participants could not be evaluated for this outcome due to loss to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>Exposed/Chemotherapy</title>
            <description>Breast cancer patients who will undergo chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Unexposed</title>
            <description>Breast cancer patients who will not undergo chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis</title>
          <description>Number of participant without of menses for 12 months after breast cancer diagnosis</description>
          <population>25 participants could not be evaluated for this outcome due to censoring for cancer recurrence, death, bilateral salpingo-oophorectomy, or hysterectomy.
38 additional participants could not be evaluated for this outcome due to loss to follow up.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience Return of Menses After 3 Months of Amenorrhea</title>
        <description>Number of participants who experience return of menses after 3 months of amenorrhea</description>
        <time_frame>Years 1-5</time_frame>
        <population>We did not undertake this analysis for participants who did not undergo chemotherapy (unexposed) or were censored for recurrence, death, hysterectomy or bilateral salpingo-oophorectomy (n=108) as this measure is not applicable</population>
        <group_list>
          <group group_id="O1">
            <title>Exposed/Chemotherapy</title>
            <description>Breast cancer patients who will undergo chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Unexposed</title>
            <description>Breast cancer patients who will not undergo chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Return of Menses After 3 Months of Amenorrhea</title>
          <description>Number of participants who experience return of menses after 3 months of amenorrhea</description>
          <population>We did not undertake this analysis for participants who did not undergo chemotherapy (unexposed) or were censored for recurrence, death, hysterectomy or bilateral salpingo-oophorectomy (n=108) as this measure is not applicable</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exposed/Chemotherapy</title>
          <description>Breast cancer patients who will undergo chemotherapy</description>
        </group>
        <group group_id="E2">
          <title>Unexposed</title>
          <description>Breast cancer patients who will not undergo chemotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Irene Su, MD MSCE</name_or_title>
      <organization>UC San Diego</organization>
      <phone>858-822-5986</phone>
      <email>hisu@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

